Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399486 | 1.00 | JAK2 (1.00) | JAK2JAK1 | |
| SCHEMBL29422151 | 0.91 | JAK2 (1.00) | JAK2JAK1 | |
| SCHEMBL2395016 | 0.91 | JAK2 (1.00) | JAK2JAK1 | |
| SCHEMBL2397686 | 0.90 | JAK2 (1.00) | JAK2JAK1 | |
| SCHEMBL29422159 | 0.90 | JAK2 (1.00) | JAK2JAK1 | |
| SCHEMBL29422076 | 0.89 | JAK2 (1.00) | JAK2JAK1 | |
| SCHEMBL2395831 | 0.89 | JAK2 (1.00) | JAK2JAK1 | |
| SCHEMBL29422242 | 0.88 | JAK2 (1.00) | JAK2JAK1 | |
| SCHEMBL2396362 | 0.88 | JAK2 (1.00) | JAK2JAK1 | |
| SCHEMBL2396792 | 0.88 | JAK2 (1.00) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2023-02-09 | — | — | US | disclosed |
| US-11285140-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE CORPORATION (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285140-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885 |
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.